Adare Pharma Solutions is a global technology-driven contract development and manufacturing organization (CDMO) providing end-to-end integrated services, from product development through commercial manufacturing and packaging, with small molecule expertise focusing on oral dosage forms for the pharmaceutical industry. Adare’s specialized technology platforms provide taste masking, customized release, multiparticulate systems, and patient-centric dosing solutions. With a proven history in drug delivery, Adare’s facilities in the US and Europe have developed and manufactured more than 65 products sold by customers worldwide.
Adare Pharma Solutions operates facilities in the U.S. and Europe, with nearly 750 global employees, providing integrated global and regional supply chains for our customers. We have the experience to guide projects from clinical research stages through optimization, validation, and approval. Our sites are equipped to facilitate efficient drug product development and manufacturing while maintaining excellent environmental conditions compliant with U.S. and EU cGMP regulations.
With DEA Licenses for the manufacture and testing of controlled substances listed in Schedules II, 2N, III, 3N, IV, and L1, Adare is authorized to develop and produce pain management and CNS therapies. Our in-house regulatory and quality teams have a proven global track record, assuring our clients that products we manufacture are provided with the highest relevant standards for patient care throughout the world.
Adare offers a full range of solid-dose commercial contract packaging, including bottles, blister packs, stick packs, and packaging of DEA schedules II, 2N, III, 3N, IV, and L1.
Europe represents an important market for Adare Pharma Solutions, and we are actively investing in the continued enhancement of our oral dose capabilities in the region. Recent expansions to our Pessano site in Milan include a 2,800 square meter extension that houses a new packaging line in a purpose-built hall, as well as a 1,000 square meter warehouse that provides capacity for 900 pallets. In addition, a high-shear mixer granulator has been added to the site to complement its existing fluid bed capabilities.
Adare now offers clinical-scale cGMP 3D screen printing, an innovative technology that empowers a wide range of enhanced dose flexibility capabilities, including complex multi-layered formulations, precision control overdrug release profiles, near endless possibilities in dosage form shaping, and tailored formulations for specific therapeutic needs.
Tom Sellig, Adare’s chief executive officer, is a thirty-year veteran of the pharmaceutical and lifesciences industries, with a focus on the CDMO sector. “Adare has developed innovative solutions that help leading pharmaceutical companies make transformative medicines more widely and readily available to patients,” Sellig said. “As we move into the future, Adare’s goal will continue to be helping our customers widen access to critical health care.”
